Price changes

1. upcoming from January 1, 2027

   Germany: fixed dental subsidy falls to 50/60/65%

   For treatment plans approved from January 1, 2027, statutory insurance pays 50% of the standard-care amount, 60% or 65% with a five- or ten-year check-up record — down from 60/70/75%. Plans approved earlier keep the old rates; hardship cases still get the full standard-care amount.

   Affects: Dental implants · All-on-4 · Crowns

   Source: Bundesgesetzblatt 2026 I Nr. 228 (GKV-Beitragssatzstabilisierungsgesetz), Art. 1 Nr. 22/23, Art. 8 Abs. 2

2. upcoming from January 1, 2027

   Medicare negotiated price ends for Xarelto, Entresto, Stelara and NovoLog

   CMS's maximum-fair-price file ends Medicare's negotiated prices for Xarelto ($197), Entresto ($295), Stelara ($4,695) and NovoLog/Fiasp ($119, each per 30-day supply) on December 31, 2026 and marks the drugs as deselected. From 2027 what enrollees pay depends on their Part D plan; the $35 monthly cap for covered insulin continues under separate rules.

   Affects: Xarelto · Entresto · Stelara · NovoLog

   Source: CMS — Selected drug list and maximum fair price data file, 2.11.2026 / November 2, 2026

3. upcoming from January 1, 2027

   Medicare negotiated prices rise with inflation

   From January 1, 2027, CMS adjusts six of Medicare's first ten negotiated prices for inflation (30-day supply): Eliquis $231 → $237.25, Jardiance $197 → $202.33, Januvia $113 → $116.06, Farxiga $178.50 → $183.33, Enbrel $2,355 → $2,418.70, Imbruvica $9,319 → $9,571.07.

   Affects: Eliquis · Jardiance · Januvia · Farxiga · Enbrel · Imbruvica

   Source: CMS — Selected drug list and maximum fair price data file, 2.11.2026 / November 2, 2026

4. upcoming from January 1, 2027

   Medicare negotiated price for semaglutide takes effect

   From January 1, 2027, Medicare's negotiated price for semaglutide (Ozempic, Rybelsus, Wegovy) applies: $274 for a 30-day supply, 71% below the 2024 list price; $385.63 for a Wegovy pack of four 2.4 mg pens.

   Affects: Ozempic · Wegovy & Zepbound

   Source: CMS — Negotiated prices for initial price applicability year 2027 (fact sheet)

5. upcoming from January 1, 2027

   US list price of Ozempic and Wegovy falls to $675

   Novo Nordisk announced that the US list price of Ozempic, Wegovy and Rybelsus falls to $675 a month for all doses from January 1, 2027 — about 35% lower for Ozempic.

   Affects: Ozempic · Wegovy & Zepbound

   Source: Novo Nordisk, Pressemitteilung / press release, 24.2.2026

6. upcoming from January 1, 2027

   Germany: prescription co-payment rises to €7.50–€15

   From January 1, 2027, people with statutory insurance in Germany pay 10% of the price per pack, at least €7.50 and at most €15 — up from €5–€10; never more than the price itself.

   Affects: EpiPen · Insulin · Inhaler

   Source: Bundesgesetzblatt 2026 I Nr. 228 (GKV-Beitragssatzstabilisierungsgesetz), Art. 1 Nr. 22/23, Art. 8 Abs. 2

7. upcoming from January 1, 2027

   Germany: hospital co-payment rises to €15 a day

   From January 1, 2027, the co-payment for an inpatient hospital stay is €15 per calendar day instead of €10, still for at most 28 days a year — up to €420 instead of €280.

   Affects: Knee replacement · Hip replacement · Spinal fusion

   Source: Bundesgesetzblatt 2026 I Nr. 228 (GKV-Beitragssatzstabilisierungsgesetz), Art. 1 Nr. 22/23, Art. 8 Abs. 2

8. in effect since July 1, 2026

   Medicare: $50 copay for weight-loss GLP-1s (temporary)

   Since July 1, 2026, Medicare enrollees pay a $50 copay for certain weight-loss GLP-1 drugs (Wegovy, Zepbound KwikPen, Foundayo) — a temporary program running through December 31, 2027.

   Affects: Wegovy & Zepbound · Mounjaro

   Source: CMS — Medicare GLP-1 Bridge

Cost information, not legal or medical advice. As of November 5, 2026.